Cellaria Biosciences works closely with cancer researchers to understand their unique and pressing challenges. These investigators face an uphill battle in bringing life-saving drugs to market—a process that can cost billions of dollars and take up to 10 years. However, the established testing models in use have limited relevance. To accelerate new progress in cancer research, scientists seek a new type of testing model; one that reflects the complexity of cancer and the unique needs of each patient.
Cancer researchers and scientists continue to rely on current cell lines, patient-derived xenografts (PDX), and mouse models as part of their testing methods. However, each of these long-used models has its limitations and drawbacks.
Current Cancer Drug Discover Tools
WATCH OUR VIDEO about how Cellaria fills the gap that exists from the limitations and setbacks of current research methods.
Where established testing methods fall short, Cellaria fills the gap. Our patient-specific models accelerate the pace and progress of cancer research by meeting these key benchmarks:
Offering sustained growth through innovation and optimization
The limited availability of representative tumor-derived cell lines constrains the scope of research in a very patient-specific disease. Some rarer sub-types of cancer have no models available at all.
Cellaria’s technology enables greater success in generating cell models from patient tumors, for both easy and difficult to grow cancer types. By supporting robust growth of multiple cell types within the tumor, our media and proprietary methods prevent cell death and large-scale cell selection within culture.
Documented quality and reproducibility
The lack of reproducible results is tied to a myriad of issues, including, wide-spread cell line cross-contamination, mycoplasma contamination, and variations in lot-to-lot performance.
Cellaria provides extensive quality testing to ensure the best performance in every lot of cells. In addition to testing for mycoplasma and all major forms of microbial and human viral contamination, we utilize STR fingerprinting to confirm the identity of your cells. We go the extra mile by providing expected growth performance that is confirmed to three passages after thaw, which can be achieved through our tailored protocols.
Informed cell model characterization that reflect clinical attributes
Our scientists work using the primary tumor as a reference, preserving the cancer cells within the tumor sample. Our model is accompanied by extensive clinical information and highlights of critical mutations and molecular markers. With Cellaria’s models, scientists can further translate research across varying patient populations.
Cellaria offers two types of Media—Renaissance Essential Tumor Medium (RETM) and WIT Culture Media. RETM is used for the successful derivation of cancer cells and is specifically designed for extended in vitro propagation. It uses a simple, feeder-free protocol for a wide breadth of tumor types and produces cultures with less variability and more reproducible results. WIT Culture Media are optimized for the expansion of normal human mammary epithelial cells and human fallopian tissue. Completely defined and serum-free, this type of media has been used for a broad range of applications by scientists, including growth of lymphoma and mouse tumor tissue.
Connect With Us
Learn more about how Cellaria can help transform your research efficacy.